Arjo AB (publ) (ARRJF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 19.65 means the share price is 19.65 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $776M is the value of all shares combined. Beta 0.77: the stock has moved about 23% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerArjo AB (publ) (ARRJF) trades at $2.85 with MoonshotScore 43/100 (Grade C). Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges. Market cap: $776M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for ARRJF: ARRJF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARRJF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
ARRJF: 1/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Arjo AB (publ) (ARRJF) Healthcare & Pipeline Overview
Arjo AB (publ) is a global medical device company focused on providing solutions for patients with reduced mobility and age-related health challenges. With a presence in North America, Western Europe, and other international markets, Arjo offers a comprehensive portfolio of products and services for acute and long-term care facilities.
What Is the Investment Thesis for ARRJF?
Arjo AB (publ) presents a notable research candidate driven by the increasing global demand for healthcare solutions for aging populations and patients with reduced mobility. With a current P/E ratio of 19.65 and a dividend yield of 3.67%, the company offers a blend of value and income potential. Growth catalysts include expansion into emerging markets and the introduction of innovative products addressing unmet needs in patient care. The company's strong market position and established distribution network provide a solid foundation for future growth. However, investors should be aware of potential risks such as increased competition and regulatory changes in the healthcare industry. Arjo's ability to maintain its profit margin of 3.0% and capitalize on growth opportunities will be crucial for long-term success.
Based on FMP financials and quantitative analysis
ARRJF Key Highlights
Market capitalization of $776M reflects Arjo's established presence in the medical device market.
- P/E ratio of 19.65 indicates a reasonable valuation compared to its earnings.
- Gross margin of 40.9% demonstrates Arjo's ability to maintain profitability in a competitive market.
- Dividend yield of 3.67% provides an attractive income stream for investors.
- Beta of 0.77 suggests lower volatility compared to the overall market.
Who Are ARRJF's Competitors?
ARRJF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| EXETF Extendicare Inc. | $22.20 | -0.05% | $2.11B | — |
| LFTSF LifeTech Scientific Corporation | $0.23 | 0.00% | $1.03B | — |
| NNCSF Nanosonics Limited | $1.93 | +7.25% | $577M | — |
| PHCI Panamera Holdings Corporation | $2.50 | 0.00% | $185M | — |
| RKAGY RHON-KLINIKUM AG Unsponsored ADR | $8.16 | 0.00% | $1.09B | — |
| MEDOF Medios AG | $50.00 | 0.00% | $1.28B | 459-signal |
| PBH Prestige Consumer Healthcare Inc. | $47.34 | -2.79% | $2.24B | 625-pillar |
| GRDN Guardian Pharmacy Services, Inc. | $43.66 | -0.39% | $2.76B | 965-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ARRJF's Key Strengths?
Strong brand reputation and established market presence.
- Comprehensive product portfolio addressing diverse patient needs.
- Extensive distribution network across key geographic markets.
- Focus on innovation and customer satisfaction.
What Are ARRJF's Weaknesses?
Relatively low profit margin compared to industry peers.
- Dependence on healthcare spending and reimbursement policies.
- Exposure to currency fluctuations and economic cycles.
- Limited presence in emerging markets compared to larger competitors.
What Could Drive ARRJF Stock Higher?
Launch of new product lines targeting specific patient needs in Q4 2026.
- Expansion of distribution network in emerging markets throughout 2026.
- Strategic partnerships with healthcare providers to enhance service offerings.
- Publication of clinical trial results demonstrating the efficacy of Arjo's solutions in Q3 2026.
What Are the Key Risks for ARRJF?
Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Increased competition from established and emerging players in the medical device industry.
- Stringent regulatory requirements and evolving industry standards.
- Economic downturns and healthcare budget cuts impacting demand for Arjo's products.
- Currency fluctuations affecting revenue and profitability.
- Dependence on key suppliers and potential supply chain disruptions.
What Are the Growth Opportunities for ARRJF?
- Expansion into emerging markets: Arjo has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is rapidly developing and the demand for advanced medical devices is increasing. By establishing strategic partnerships and tailoring its product offerings to local needs, Arjo can tap into new revenue streams and accelerate its growth trajectory. This expansion could target a market size of $10 billion by 2030.
- Development of innovative products: Arjo can invest in research and development to create innovative products that address unmet needs in patient care. By focusing on areas such as pressure injury prevention, infection control, and mobility assistance, Arjo can differentiate itself from competitors and capture a larger share of the market. Launching two new product lines annually could increase revenue by 15% by 2028.
- Strategic acquisitions: Arjo can pursue strategic acquisitions to expand its product portfolio, enhance its geographic reach, and gain access to new technologies. By acquiring complementary businesses, Arjo can strengthen its competitive position and create synergies that drive growth. Targeting acquisitions of companies with revenues between $50 million and $100 million annually could add 10% to revenue by 2027.
- Enhancement of service offerings: Arjo can enhance its service offerings, such as clinical consulting, maintenance, and equipment rental, to provide added value to its customers. By offering comprehensive solutions that address the entire patient care continuum, Arjo can strengthen its customer relationships and generate recurring revenue streams. Increasing service revenue by 20% annually could stabilize and increase profit margins by 2029.
- Digitalization of healthcare solutions: Arjo can leverage digital technologies to enhance its healthcare solutions and improve patient outcomes. By developing connected devices, data analytics platforms, and remote monitoring systems, Arjo can provide real-time insights and personalized care recommendations. Integrating AI-powered solutions could improve efficiency by 10% by 2028.
What Are ARRJF's Competitive Advantages?
- Established brand reputation in the medical device industry.
- Comprehensive product portfolio addressing a wide range of patient needs.
- Extensive distribution network across North America, Western Europe, and other international markets.
- Strong relationships with key customers in the healthcare sector.
What Does ARRJF Do?
Founded in 1957 and headquartered in Malmö, Sweden, Arjo AB (publ) has evolved into a leading provider of medical devices and solutions catering to patients with mobility issues and age-related conditions. The company's comprehensive product portfolio includes patient handling equipment, hygiene solutions, disinfection systems, medical beds, and solutions for pressure injury prevention and treatment. Arjo also offers products for deep vein thrombosis prevention, edema treatment, obstetric diagnostics, and cardiac diagnostics. Arjo serves a diverse range of customers, including private and public institutions providing acute and long-term care. Its solutions are designed to improve patient outcomes, enhance caregiver efficiency, and promote a safe and comfortable environment. The company's geographic reach extends across North America, Western Europe, and other international markets, reflecting its commitment to serving a global customer base. Arjo's dedication to innovation and customer satisfaction has solidified its position as a trusted partner in the healthcare industry.
What Products and Services Does ARRJF Offer?
- Develops and sells medical devices for patients with reduced mobility.
- Offers solutions for age-related health challenges.
- Provides patient handling equipment and hygiene solutions.
- Manufactures and distributes medical beds and disinfection systems.
- Offers products for pressure injury and leg ulcer treatment and prevention.
- Provides solutions for deep vein thrombosis prevention and edema treatment.
- Offers obstetric and cardiac diagnostic equipment.
- Provides clinical consulting, maintenance, and equipment rental services.
How Does ARRJF Make Money?
- Develops and manufactures medical devices and solutions.
- Sells products and services to private and public healthcare institutions.
- Generates revenue through product sales, service contracts, and equipment rentals.
- Focuses on providing comprehensive solutions for patient care.
What Industry Does ARRJF Operate In?
Arjo AB (publ) operates within the medical device industry, which is experiencing steady growth driven by an aging global population and increasing demand for healthcare services. The market for patient handling and mobility solutions is particularly robust, with a growing emphasis on improving patient safety and caregiver efficiency. Arjo competes with companies like EXETF, LFTSF, NNCSF, PHCI, and RKAGY, focusing on innovation and customer service to maintain its competitive edge. The industry is subject to stringent regulatory requirements and evolving technological advancements, requiring companies to adapt and innovate to remain competitive.
Who Are ARRJF's Key Customers?
- Private hospitals and clinics
- Public healthcare institutions
- Long-term care facilities
- Rehabilitation centers
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in SEK, converted to USD
Why 43?
This rating comes from our nine-signal model, which produces a score but not a per-factor breakdown. The sector-relative five-pillar model, which explains its own contributions, does not cover this listing yet. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 43 |
| 2026-08-26 | 43 |
| 2026-08-29 | 43 |
| 2026-09-01 | 43 |
| 2026-09-04 | 43 |
| 2026-09-07 | 43 |
| 2026-09-10 | 43 |
What changed?
The score has stayed at 43.
Over the same 18 days the stock moved -1.5%.
Arjo AB (publ) (ARRJF) Valuation Context
Valued at $776M, ARRJF is classified as a small-cap stock. Relative to its peer group, ARRJF's quantitative score of 43/100 is below the peer average of 68/100.
ARRJF Revenue & Earnings Trend
In Q2 FY2026, ARRJF generated $282.7M in top-line revenue, marking a sequential increase of 1.9%. The company recorded net income of $12.8M, with diluted EPS of $0.05. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ARRJF averaged $0.04 in diluted EPS.
Company Profile
Arjo AB (publ) operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Malmö, SE. The company is led by CEO Andreas Elgaard. ARRJF has traded publicly since 2018.
Key Financial Metrics
Return on equity for Arjo AB (publ) stands at 4.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.3%, showing how much profit it generates from its asset base. ARRJF trades at a trailing price-to-earnings ratio of 19.65, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 16.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Arjo AB (publ)'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.18 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Arjo AB (publ) has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 19.3% below estimates on average.
ARRJF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand reputation and established market presence.
- Comprehensive product portfolio addressing diverse patient needs.
- Extensive distribution network across key geographic markets.
- Focus on innovation and customer satisfaction.
Bear Case
- Relatively low profit margin compared to industry peers.
- Dependence on healthcare spending and reimbursement policies.
- Exposure to currency fluctuations and economic cycles.
- Limited presence in emerging markets compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $283M | $13M | $0.05 |
| Q1 FY2026 | $277M | $11M | $0.04 |
| Q4 FY2025 | $290M | $7M | $0.03 |
| Q3 FY2025 | $271M | $8M | $0.03 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from SEK at today's rate
ARRJF Latest News
-
Arjo AB (publ) (ARRJF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 14, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Dec 10, 2019
ARRJF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ARRJF.
Price Targets
Wall Street price target analysis for ARRJF.
ARRJF MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. ARRJF scores 43/100 (Grade C): the number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Leadership: Andreas Elgaard
CEO
Andreas Elgaard is the CEO of Arjo AB (publ). He brings extensive experience in the healthcare industry, with a proven track record of driving growth and innovation. Prior to joining Arjo, Andreas held leadership positions at various medical device companies, where he focused on developing and commercializing innovative healthcare solutions. He holds an MBA from a leading business school and a degree in engineering.
Track Record: Under Andreas Elgaard's leadership, Arjo has focused on expanding its global presence and strengthening its product portfolio. He has overseen the launch of several new products and services, and has implemented strategic initiatives to improve operational efficiency and enhance customer satisfaction. His focus on innovation and customer-centricity has contributed to Arjo's continued success in the competitive healthcare market.
ARRJF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arjo AB (publ) may not meet the minimum financial reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity may be less frequent and transparent compared to exchange-listed companies. This tier is often associated with higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise caution and conduct thorough due diligence before investing in companies trading on the OTC Other tier.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Potential for price volatility and manipulation.
- Higher risk of fraud or misrepresentation.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Monitor trading activity and price movements.
- Established history of operations since 1957.
- Presence in North America, Western Europe, and internationally.
- Positive analyst coverage and industry recognition.
- Commitment to innovation and customer satisfaction.
Arjo AB (publ) Healthcare Stock: Key Questions Answered
What does the AI Score mean for ARRJF?
ARRJF holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. The number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed. Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges.
Is ARRJF a good stock?
Stock Expert AI does not rate ARRJF buy, sell or hold. Arjo AB (publ) carries a MoonshotScore of 43/100 on the legacy nine-factor engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for ARRJF?
The main risks for ARRJF include increased competition in the medical device industry, which could put pressure on pricing and market share. Economic downturns and healthcare budget cuts could impact demand for Arjo's products and services.
What are the key factors to evaluate for ARRJF?
Arjo AB (publ) (ARRJF) holds a MoonshotScore of 43/100 (low). P/E: 19.65x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ARRJF data refresh on this page?
ARRJF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ARRJF's recent stock price performance?
Arjo AB (publ) (ARRJF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation and established market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARRJF overvalued or undervalued right now?
Arjo AB (publ) (ARRJF) trades at 19.65x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ARRJF?
Yes, most major brokerages offer fractional shares of Arjo AB (publ) (ARRJF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ARRJF's earnings and financial reports?
Arjo AB (publ) (ARRJF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ARRJF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to OTC status.
- Analyst opinions may vary.